Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma

Wolf, Armin; Jagow, Burkhard von; Ulbig, M; Haritoglou, Christos

doi:10.1159/000327364

Cited by 32 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab is frequently used in neovascular conditions; for example, intracameral bevacizumab administered 24 hours prior to filtration surgery has been reported to effectively prevent rebleeding (26). Similarly, intravitreal and intracameral bevacizumab have been demonstrated to induce regression of iris neovascularization (27)(28)(29). Based on our findings, we believe that a current hyphema must be surgically removed prior to injection of bevacizumab if the hyphema is present in the neovascular state.…”

Section: Discussionsupporting

confidence: 53%

The effect of intracameral bevacizumab on current hyphema

Polat¹,

Özkan²,

Akbaş³

et al. 2019

Ann Med Res

View full text Add to dashboard Cite

The aim of this study was to investigate the effect of intracameral bevacizumab on the current hyphema. Material and Methods: The animals were assigned to the following 4 groups; Group 1: One 2.5 mg bevacizumab injection to the anterior chamber; Group 2: One 1.25 mg bevacizumab injection to the anterior chamber; Group 3: One 1cc balanced salt solution injection to the anterior chamber; and Group 4: Untreated hyphema group. Non-heparinized blood that obtained from the rabbit ear was used to fill the anterior chamber to create total hyphema. Intraocular pressures (IOP), hyphema resorption time, clot formation, peripheral synechia formation, and corneal staining were recorded. Results: IOP results were 26±1.2, 30±2.1, 24±2.9, and 22±0.0 mm Hg for groups 1, 2, 3, and 4, respectively, and were significantly higher in group 2 than in the other groups (p= 0.001). Resorption times of hyphema were 13±2.2, 13±3.2, 9±1.7, and 9±1.6 days for groups 1, 2, 3, and 4, respectively, and were significantly longer for the groups receiving bevacizumab than for the others (p=0.018). The clot formation scores were 0.16±0.41, 0.14±0.38, 0.86±0.38, and 1.0±0.0 for groups 1, 2, 3, and 4, respectively, and were significantly lower for the groups receiving bevacizumab than in the other groups (p= 0.002). The peripheral synechia formation scores were 0.0±0.0, 0.0±0.0, 0.43±0.53, and 0.50±0.54 for groups 1, 2, 3, and 4, respectively, and were not significantly different (p= 0.213). The corneal staining scores were 0.85±0.35, 0.86±0.38, 0.14±0.38, and 0.14±0.38 for groups 1, 2, 3, and 4, respectively, and were significantly higher for the groups receiving bevacizumab (p= 0.035). Conclusion: Intracameral bevacizumab may increase complications that related current hyphema.

show abstract

Section: Discussionsupporting

confidence: 53%

The effect of intracameral bevacizumab on current hyphema

Polat¹,

Özkan²,

Akbaş³

et al. 2019

Ann Med Res

View full text Add to dashboard Cite

show abstract

“…However, due to our relatively small sample size and the inherently qualitative nature of immunohistochemical staining, we were unable to detect any obvious quantitative differences in relative VEGFR receptor expression level between canine eyes suffering these various diseases. Prevention and reversal of angiogenesis by antagonizing the effects of intraocular VEGF expression has become a popular therapeutic strategy in human ophthalmic disease for numerous intraocular neovascular conditions, including rubeosis iridis and neovascular glaucoma, the human counterpart to canine PIFM 46–48 . In addition, beneficial effects of VEGF Trap, an antibody that binds VEGFR1 and VEGFR2 resulting in neutralization of VEGF, has recently been demonstrated in a canine model of oxygen‐induced retinopathy 49 .…”

Section: Discussionmentioning

confidence: 99%

Expression of vascular endothelial growth factor receptor‐1 and ‐2 in normal and diseased canine eyes

Binder¹,

Herring²,

Zimmerman

et al. 2011

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…127.4). 82 Therefore, the intracameral application of VEGF inhibitors may extend our therapeutic options in the management of neovascular glaucoma, especially as other options such as photocoagulation of ischemic retinal areas alone may not be enough to prevent the progression of neovascular However, recurrence of increased IOP is frequent.…”

Section: Neovascular Glaucomamentioning

confidence: 99%